Trial intelligence / Profile preview

Swedish Exelon Titration Study

2004-001383-46Phase 4Completed

Sponsor
Karolinska University Hospital
Start
Aug 2004
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4 trial of rivastigmine in Alzheimer's disease (AD), sponsored by Karolinska University Hospital. Primary endpoints: Optimal dose-escalation interval for rivastigmine and Impact of Helicobacter pylori infection on gastrointestinal side effects. Started Aug 2004; status: completed.

02

Drugs

rivastigmine
03

Conditions

Alzheimer's disease (AD)

Beyond the preview

Go deeper on 2004-001383-46.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2004-001383-46.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call